ResearcherActive in the last 2 years

Eric Keith Rowinsky

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0848-4826; OpenAlex author ID A5011905014. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ann Marie Leen · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Angelica Loskog · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Emma Eriksson · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Gustav Jörgen Ullenhag · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Linda C. Sandin · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Mohamed O. Othman · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Brandon George Smaglo · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Benjamin Musher · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Andrew H. Ko · 1 shared paper, 2012 · strength 0.03
- Paper A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy… DOI 10.1007/s10637-011-9691-8 ↗
Omar Roger Kayaleh · 1 shared paper, 2012 · strength 0.03
- Paper A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy… DOI 10.1007/s10637-011-9691-8 ↗
Heinz‐Josef Lenz · 1 shared paper, 2012 · strength 0.03
- Paper A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy… DOI 10.1007/s10637-011-9691-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.